Compare AMPG & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | IOBT |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 57.2M |
| IPO Year | N/A | 2021 |
| Metric | AMPG | IOBT |
|---|---|---|
| Price | $2.66 | $0.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 1.1M | ★ 28.1M |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,571,945.00 | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.47 | N/A |
| 52 Week Low | $1.21 | $0.21 |
| 52 Week High | $4.89 | $2.79 |
| Indicator | AMPG | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 42.46 |
| Support Level | $2.70 | $0.34 |
| Resistance Level | $3.16 | $0.40 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 3.90 | 56.71 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.